Everolimus shortens survival of newly diagnosed glioblastoma patients
To the Editor,
RTOG 0913 is a randomized phase II trial testing the effects of everolimus added to standard radiotherapy with concurrent and adjuvant temozolomide for newly diagnosed glioblastomas . As pointed out by the authors, this is the largest study to date investigating the efficacy of an mTOR inhibitor for glioblastoma. Unfortunately, everolimus did not improve either PFS or OS in the trial subjects. In fact, those taking the medication died sooner by an average of 4.7 months and they experienced more frequent grade 4 and 5 adverse events. Among them, serious infections were more common in the experimental group than in the control population.
Preclinical work has shown that mTOR functions to transduce signals in glioma cells that are necessary for their survival and proliferation. Logically, an inhibitor of mTOR like everolimus (marketed as Afinitor®, https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022334s016lbl.pdf) might be expected to halt tumor progression...
Compliance with ethical standards
Conflict of interest
All authors declare that they have no conflicts of interest.
This article does not contain any studies with human participants performed by any of the authors.